Pancreatic cancer risk and ABO blood group alleles: results from the pancreatic cancer cohort consortium.
Pancreatic cancer risk and ABO blood group alleles: results from the pancreatic cancer cohort consortium.
复制标题
DOI：
10.1158/0008-5472.can-09-2993
复制
发表时间：
2010-02-01
期刊：
影响因子：
11.2
通讯作者：
Fuchs CS
中科院分区：
文献类型：
--
作者：
Wolpin BM;Kraft P;Gross M;Helzlsouer K;Bueno-de-Mesquita HB;Steplowski E;Stolzenberg-Solomon RZ;Arslan AA;Jacobs EJ;Lacroix A;Petersen G;Zheng W;Albanes D;Allen NE;Amundadottir L;Anderson G;Boutron-Ruault MC;Buring JE;Canzian F;Chanock SJ;Clipp S;Gaziano JM;Giovannucci EL;Hallmans G;Hankinson SE;Hoover RN;Hunter DJ;Hutchinson A;Jacobs K;Kooperberg C;Lynch SM;Mendelsohn JB;Michaud DS;Overvad K;Patel AV;Rajkovic A;Sanchéz MJ;Shu XO;Slimani N;Thomas G;Tobias GS;Trichopoulos D;Vineis P;Virtamo J;Wactawski-Wende J;Yu K;Zeleniuch-Jacquotte A;Hartge P;Fuchs CS
最近的一项全基因组关联研究（PanScan）确定了ABO基因位点与胰腺癌风险的显著关联;然而，这些关联的机制和特定ABO基因型的影响仍然未知。我们确定了1534例病例和1583例对照的ABO基因型（OO，AO，AA，AB，BO，BB），这些病例和对照来自参与PanScan的12项前瞻性队列研究。我们还按基因型衍生的血清血型（O、A、AB、B）对参与者进行分组。使用logistic回归计算ABO等位基因对胰腺癌的校正比值比（OR）。与O型血相比，A型、AB型和B型受试者中胰腺癌的OR分别为1.38（95%置信区间[CI]，1.18-1.62）、1.47（95% CI，1.07-2.02）和1.53（95% CI，1.21-1.92）。O型、A型、AB型和B型的发生率（例/100，000例受试者/年）分别为28.9、39.9、41.8和44.5。每增加一个非O等位基因，风险增加。与OO相比，AO和AA受试者的OR分别为1.33（95% CI，1.13-1.58）和1.61（95% CI，1.22-2.18），而BO和BB受试者的OR分别为1.45（95% CI，1.14-1.85）和2.42（1.28-4.57）。非O型血的人群归因分数为19.5%。在吸烟的联合模型中，与O型血的非吸烟者相比，非O型血的当前吸烟者的校正OR为2.68（95%CI，2.03-3.54）。在一个大型前瞻性队列研究的参与者中，ABO基因型与胰腺癌风险显著相关。
A recent genome-wide association study (PanScan) identified significant associations at the ABO gene locus with pancreatic cancer risk; however, the mechanisms underlying these associations and the influence of specific ABO genotypes remain unknown. We determined ABO genotypes (OO, AO, AA, AB, BO, BB) in 1534 cases and 1583 controls from 12 prospective cohort studies participating in PanScan. We also grouped participants by genotype-derived serologic blood type (O, A, AB, B). Adjusted odds ratios (ORs) for pancreatic cancer by ABO alleles were calculated using logistic regression. Compared to blood type O, the ORs for pancreatic cancer in subjects with types A, AB, and B were 1.38 (95% confidence interval [CI], 1.18-1.62), 1.47 (95% CI, 1.07-2.02), and 1.53 (95% CI, 1.21-1.92), respectively. The incidence rates (cases per 100,000 subjects per year) for blood types O, A, AB, and B were 28.9, 39.9, 41.8, and 44.5. An increase in risk was noted with the addition of each non-O allele. Compared to OO, subjects with AO and AA had ORs of 1.33 (95% CI, 1.13-1.58) and 1.61 (95% CI, 1.22-2.18), while subjects with BO and BB had ORs of 1.45 (95% CI, 1.14-1.85) and 2.42 (1.28-4.57). The population attributable fraction for non-O blood type was 19.5%. In a joint model with smoking, current smokers with non-O blood type had an adjusted OR of 2.68 (95% CI, 2.03-3.54), compared with non-smokers with blood type O. Among participants in a large prospective cohort consortium, ABO genotypes were significantly associated with pancreatic cancer risk.